NEW YORK (GenomeWeb News) – PerkinElmer has acquired NTD Laboratories and J.N. Macri Technologies for around $56.65 million, bringing the company closer to its goal of building a “screening and diagnostics capability in maternal health,” PerkinElmer said today.
Separately today, PerkinElmer said Texas has selected it to supply instruments and reagents for its enhanced newborn screening program.
J.N. Macri Technologies holds global patents related to free beta Human Chorionic Gonadotropin, a peptide hormone produced in the early stage of pregnancy that is “widely recognized as a critical biomarker for first-trimester prenatal risk assessment,” according to PerkinElmer.
NTD Laboratories, on the other hand, developed UltraScreen, a screening test that when used with ultrasound and maternal demographic data provides clinicians with a patient-specific risk probability for fetal abnormalities.
With these companies, PerkinElmer can develop screening and diagnostics capabilities in maternal health.
Meantime, under the multi-year agreement with Texas, PerkinElmer will supply the Texas Department of State Health Services Laboratory with tandem mass spectrometry systems, reagent kits, and software enhancements.
PerkinElmer has similar agreements with eight other states, including Alabama, California, Florida, Kentucky, Louisiana, Missouri, Pennsylvania and South Carolina.